id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-0533-0003,FDA,FDA-2016-E-0533,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-05-02T04:00:00Z,2016,5,2016-05-02T04:00:00Z,,2016-05-02T22:24:04Z,,0,0,0900006481fa10f6
FDA-2016-E-0533-0001,FDA,FDA-2016-E-0533,Patent Extension Application from Frommer Lawrence & Haug LLP (on behalf of BioCryst Pharmaceuticals Inc.),Other,Application,2016-02-16T05:00:00Z,2016,2,2016-02-16T05:00:00Z,,2016-02-16T16:15:12Z,,0,0,0900006481e61274
FDA-2016-E-0533-0002,FDA,FDA-2016-E-0533,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-02-16T05:00:00Z,2016,2,2016-02-16T05:00:00Z,,2016-02-16T16:16:58Z,,0,0,0900006481e60fbd